Mannkind MNKD Onbody Infusor — Intangible Amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Mannkind’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335054
Amortization expense related to the Developed technology – on-body infusor ("on-body infusor") was $4.3 million and $8.6 million for the three and six months ended June 30, 2026, respectively. The on-body infusor was acquired from scPharma in October 2025. See Note 2 – Business Combinations. The estimated annual amortization expense for the on-body infusor will be approximately $17.3 million per year for the years ending December 31, 2026 through 2036. Amortization expense related to the Developed technology – V-Go was de minimis and $0.1 million for the three and six months ended June 30, 2026 and de minimis and $0.1 million for the three and six months ended June 30, 2025. The estimated annual amortization expense for the Developed technology – V-Go will be approximately $0.2 million per year for the years ending December 31, 2026 through 2029.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Mannkind's onbody infusor — intangible amortization?
- Mannkind (MNKD) reported onbody infusor — intangible amortization of $4.3M in Q2 2026.
- How has Mannkind's onbody infusor — intangible amortization changed year-over-year?
- Mannkind's onbody infusor — intangible amortization increased by 330.0% year-over-year, from $1M to $4.3M.
- What does onbody infusor — intangible amortization mean?
- This represents the periodic non-cash expense recognized during the reporting period to allocate the cost of the Onbody Infusor segment's finite-lived intangible assets over their useful lives. It reflects the systematic consumption of the economic benefits derived from these specific assets. This metric is essential for understanding the impact of intangible asset depreciation on the segment's reported operating profitability.
Ask your AI about Mannkind's onbody infusor — intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
